John Newman Analyst PerformanceAnalyst at Canaccord Genuity GroupJohn Newman is a stock analyst at Canaccord Genuity Group focused in the healthcare sector, covering 37 publicly traded companies. Over the past year, John Newman has issued 38 stock ratings, including buy and hold recommendations. While full access to John Newman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights John Newman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings230 Last 11 YearsBuy Recommendations89.38% 202 Buy RatingsCompanies Covered37 Unique Companies Ratings Distribution226RatingsDistribution of strong buy, buy, hold, and sell ratings by John Newman.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.4%202 ratings Hold10.6%24 ratings Sell0.0%0 ratingsOut of 226 total stock ratings issued by John Newman at Canaccord Genuity Group, the majority (89.4%) have been Buy recommendations, followed by 10.6% Hold.Best & Worst CallsBest Call0000.0%DARENov 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%DAREMay 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ86.5% of companies on NASDAQ32 companiesNYSE8.1% of companies on NYSE3 companiesNYSEAMERICAN2.7% of companies on NYSEAMERICAN1 companyOTCMKTS2.7% of companies on OTCMKTS1 companyJohn Newman, an analyst at Canaccord Genuity Group, currently covers 37 companies listed on NASDAQ, NYSE, NYSEAMERICAN and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare36 companies97.3%Industrials1 company2.7%John Newman of Canaccord Genuity Group specializes in stock coverage within the Healthcare sector, with additional focus on Industrials companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY28 companies75.7%PHARMACEUTICALS7 companies18.9%HEALTHCARE EQUIPMENT & SUPPLIES1 company2.7%COMMERCIAL SERVICES & SUPPLIES1 company2.7% John Newman's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBNTXBioNTech8/31/2026Lower Price Target$102.07$136.00Buy$0.0000.00% ROIINCYIncyte8/20/2026Initiated Coverage$128.47$152.00Buy$0.0000.00% ROIKZIANovogen8/13/2026Initiated Coverage$12.79$29.00Buy$0.0000.00% ROIBNTXBioNTech8/5/2026Set Price Target$91.31$142.00$0.0000.00% ROIRLAYRelay Therapeutics7/16/2026Initiated Coverage$19.51$29.00Buy$0.0000.00% ROIRLAYRelay Therapeutics7/16/2026Initiated Coverage$19.37$29.00Buy$0.0000.00% ROITNGXTango Therapeutics6/29/2026Boost Price Target$31.99$46.00Buy$0.0000.00% ROITNGXTango Therapeutics6/9/2026Boost Price Target$29.69$42.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals5/19/2026Lower Price Target$626.22$875.00Buy$0.0000.00% ROIBBOTBridgeBio Oncology Therapeutics5/11/2026Initiated Coverage$7.66$23.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. BBOTBridgeBio Oncology Therapeutics5/11/2026Initiated Coverage$7.89$23.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics5/8/2026Set Price Target$9.93$13.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics5/8/2026Upgrade$8.34$13.00Buy$0.0000.00% ROIBNTXBioNTech5/6/2026Lower Price Target$93.23$158.00Buy$0.0000.00% ROILCTXLineage Cell Therapeutics4/28/2026Initiated Coverage$1.55$9.00Buy$0.0000.00% ROICMPXCompass Therapeutics4/28/2026Lower Price Target$1.82$7.00Buy$0.0000.00% ROITYRATyra Biosciences4/6/2026Initiated Coverage$39.61$50.00Buy$0.0000.00% ROITNGXTango Therapeutics4/2/2026Initiated Coverage$21.22$30.00Buy$0.0000.00% ROIMCRBSeres Therapeutics3/13/2026Reiterated Rating$8.68$22.00Buy$0.0000.00% ROICADLCandel Therapeutics3/13/2026Reiterated Rating$4.75$25.00Buy$0.0000.00% ROIALLOAllogene Therapeutics3/13/2026Reiterated Rating$2.41$14.00Buy$0.0000.00% ROIBNTXBioNTech3/11/2026Reiterated Rating$91.20$171.00Buy$0.0000.00% ROIACLXArcellx2/23/2026Set Price Target$113.82$115.00$0.0000.00% ROIACLXArcellx2/23/2026Downgrade$113.75Hold$0.0000.00% ROICMPXCompass Therapeutics2/4/2026Set Price Target$6.42$13.00$0.0000.00% ROIATRAAtara Biotherapeutics1/13/2026Reiterated Rating$4.99$6.00Hold$0.0000.00% ROIACETAdicet Bio1/6/2026Set Price Target$8.15$18.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics12/19/2025Set Price Target$17.23$25.00Buy$0.0000.00% ROIACLXArcellx12/8/2025Reiterated Rating$76.88$130.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals12/4/2025Boost Price Target$723.97$1,057.00Buy$0.0000.00% ROICMPXCompass Therapeutics12/3/2025Initiated Coverage$5.22$10.00Buy$0.0000.00% ROINUVLNuvalent11/12/2025Initiated Coverage$96.15$126.00Buy$0.0000.00% ROIACLXArcellx11/3/2025Boost Price Target$90.25$130.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals10/23/2025Reiterated Rating$584.74$850.00Buy$0.0000.00% ROIDCTHDelcath Systems10/21/2025Reiterated Rating$11.51$21.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals10/14/2025Reiterated Rating$562.31$850.00Buy$0.0000.00% ROIMRUSMerus9/29/2025Downgrade$93.56$97.00Hold$0.0000.00% ROIMCRBSeres Therapeutics9/24/2025Boost Price Target$17.56$22.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals7/23/2025Reiterated Rating$572.92$850.00Buy$000.0000.00% ROIALLOAllogene Therapeutics3/14/2025Reiterated Rating$1.90$14.00Buy$0.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfATRAAtara Biotherapeutics3/11/2025Reiterated Rating$6.16$17.00Buy$0.0000.00% ROIBNTXBioNTech3/11/2025Reiterated Rating$103.54$171.44Buy$00.0000.00% ROIMRKRMarker Therapeutics3/5/2025Initiated Coverage$1.38$8.00Buy$0.0000.00% ROICADLCandel Therapeutics2/19/2025Initiated Coverage$9.52$20.00Buy$0.0000.00% ROIATRAAtara Biotherapeutics1/17/2025Lower Price Target$6.88$17.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageRoyal Bank Of CanadaJefferies Financial GroupSeaport Research PartnersWall Street ZenCitigroupUBS GroupBarclaysMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
